Assessment of Long-term Effects (Complications) of COVID-19 in the Southern Part of Bangladesh - a Retrospective Observational Study.

August 1, 2021 updated by: Harendra Nath Sarker, Sher-E-Bangla Medical College

An outbreak of the novel coronavirus nCoV-19 (SARS-CoV-2), responsible for the coronavirus disease-19 (COVID-19), was first detected in Hubei province, Wuhan, China, on December 31, 2019. It has rapidly spread globally with approximately 157,343,044 confirmed cases and 3,278,510 deaths till 7th May, 2021 [1]. World Health Organization (WHO) declared COVID- 19 pandemic on 11th March 2020.

The world is facing the second wave of Coronavirus Disease 2019 (COVID-19) pandemic which is the most troublesome challenge to public health. The second wave is running and nobody knows where we are in the course of this disease. It becomes a significant challenge for the public health, science, and medical sectors [2].

According to the World Health Organization, about 80% of infections are mild or asymptomatic, 15% result in moderate to severe symptoms (requiring oxygen) and about 5% are critical infections, which require ventilation.

We are learning something new every day. Our understanding of the pandemic is growing and changing daily. The world is focusing on the short term - flattening the curve, treating the sick and discovering a vaccine. But there is more to this pandemic than the short term.

We know a lot about the transmission and clinical feature of COVID-19, but relatively little about what happens after someone recovers. Much is still unknown about how COVID-19 will affect people over time. There's still much to be learned from those who have recovered from COVID-19.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

B. INTRODUCTION:

An outbreak of the novel coronavirus nCoV-19 (SARS-CoV-2), responsible for the coronavirus disease-19 (COVID-19), was first detected in Hubei province, Wuhan, China, on December 31, 2019. It has rapidly spread globally with approximately 157,343,044 confirmed cases and 3,278,510 deaths till 7th May, 2021 [1]. World Health Organization (WHO) declared COVID- 19 pandemic on 11th March 2020.

The world is facing the second wave of Coronavirus Disease 2019 (COVID-19) pandemic which is the most troublesome challenge to public health. The second wave is running and nobody knows where we are in the course of this disease. It becomes a significant challenge for the public health, science, and medical sectors [2].

According to the World Health Organization, about 80% of infections are mild or asymptomatic, 15% result in moderate to severe symptoms (requiring oxygen) and about 5% are critical infections, which require ventilation.

We are learning something new every day. Our understanding of the pandemic is growing and changing daily. The world is focusing on the short term - flattening the curve, treating the sick and discovering a vaccine. But there is more to this pandemic than the short term.

We know a lot about the transmission and clinical feature of COVID-19, but relatively little about what happens after someone recovers. Much is still unknown about how COVID-19 will affect people over time. There's still much to be learned from those who have recovered from COVID-19.

We are still only one year and four months beyond the first emergence of COVID-19, so it's too early to tell what the extent of any long-term impacts will be.

Most people who have COVID-19 recover completely within a few weeks [3]. But some people - even those who had mild disease, continue to experience symptoms after their initial recovery. Older people and people with many serious medical conditions like diabetes, COPD, heart disease, kidney disease etc. are the most likely to experience these lingering COVID-19 symptoms. The most common symptoms that linger over weeks, even months are:

  • Fatigue
  • Cough (dry)
  • Shortness of breath
  • Headache
  • Joint pain
  • Muscle pain
  • Confusion and even hallucinations. But, our body has surprising healing capacity; most of these symptoms will improve by six months. However, some people recovering from COVID-19 will likely suffer from long-term health problems.

Although COVID-19 is seen as a disease that primarily affects the lungs, it can damage many other organs as well. This organ damage may increase the risk of long-term health problems. Some of the most common long-term effects are:

Lungs: The pneumonia associated with COVID-19 can often cause long-standing damage to the tiny air sacs (alveoli) in the lungs [4]. The resulting scar tissue i.e. pulmonary fibrosis can lead to long-term breathing problems.

Heart: A recent study from the University of Frankford in Germany showed abnormal heart findings in more than 75% of people studied who had recently recovered from COVID-19. Imaging tests taken months after recovery from COVID-19 have shown lasting damage to the heart muscle, even in people who experienced only mild COVID-19 symptoms. This may increase the risk of heart failure or other heart complications in the future.

Brain: COVID-19 can cause strokes [5], seizures and Guillain-Barre syndrome, even in young people. COVID-19 may also increase the risk of developing Parkinson's disease and Alzheimer's disease.

Blood clots and blood vessel problems: COVID-19 can predispose to form clots. While large clots can cause heart attacks and strokes, much of the heart damage caused by COVID-19 is believed to stem from very small clots that block tiny blood vessels (capillaries) in the heart muscle. Other organs affected by blood clots include the lungs, legs, liver and kidneys.

Psychiatric issues: Most people recovering from COVID-19 experience anxiety, depression, or cognitive impairment. Some may develop more serious Post-Traumatic Stress Disorder (PTSD) due to the trauma of the illness and treatment [6].

Kidney: Patient may develop kidney complications which could lead to a need for long-term dialysis.

A lot of things may happen in long run in those who recovered from COVID-19. Our understanding of COVID-19's long term effects will depend greatly on ongoing studies over the next decades.

C. OBJECTIVES:

  1. General Objectives:

    To assess long-term effects of COVID-19 in patients who were affected with COVID -19 (RT-PCR +ve) from 1st July to 30th December, 2020 recorded in PCR Lab of Sher-E-Bangla Medical College Hospital, Barishal i.e. six months or more before the initiation of study and recovered fully.

  2. Specific Objective:

To detect the system-based complications and assess their incidence, and compare the results with other studies in home and abroad.

D. METHODOLOGY:

Study Design: An observational retrospective study. Study Population: COVID -19 (RT-PCR +ve) patients from 1st July to 30th December, 2020 recorded in PCR Lab of Sher-E-Bangla Medical College Hospital, Barishal.

Inclusion Criteria:

  • COVID-19 (RT-PCR +ve) patients age 20 years and above.
  • Those patients whose mobile numbers are recorded in the register.
  • Those patients who/their attendants are available on mobile phone.

Exclusion Criteria:

  • Persons below 20 years of age.
  • Those patients whose mobile numbers are not recorded in the register.
  • Those patients who/their attendants are not available on mobile phone.
  • Those who died by this time from causes unrelated to COVID-19.

Sample Size (n):

To determine the sample size the following formula was followed n= n= the desired sample size z= Standard normal deviate usually set at 1.96 p= Proportion in the population; if not known, it is regarded as 0.5 (50.0%), here p is 0.27 q= 1-p d= Degree of accuracy which is considered as 0.05 According to this formula the targeted sample was 302. But attempt will be taken to take more sample population as far as possible.

Sampling Technique:

Simple random sampling.

Place of Study:

Sher-E-Bangla Medical College Barishal Bangladesh.

Time-frame & Duration:

6 months from 1st July to 30th December 2021.

Research Instrument:

  1. Record register of PCR lab
  2. Printed questionnaire
  3. Mobile phone
  4. Prescription of registered doctor if any
  5. Investigations if any.

Case definition:

  1. Long-term effects of COVID-19 are those complications which develop or persist after 6 (six) months of COVID-19.
  2. System-based complications should follow the standard definition and are listed in the questionnaire.

Statistical Analysis:

Statistical analyses will be carried out by using the Statistical Package for Social Sciences version 23 for Windows (SPSS Inc., Chicago, Illinois, USA). The mean and Standard deviation values will be calculated for continuous variables. t- test and analysis of variance (ANOVA) will be employed for continuous data. P values <0.05 was considered as statistically significant.

E. PROCEDURE:

The proposed study will be conducted in Sher-E-Bangla Medical College, Barishal, Bangladesh. Those who were RT-PCR positive for corona in PCR Lab of Sher-E-Bangla Medical College, Barishal from 1st July to 30th December, 2020 and recovered fully, will be listed from register of PCR Lab and their contact numbers will be collected from there. They will be contacted via cell phone and information will be collected after initial exchange of wellbeing and verbal consent. The conversation will be conducted by a registered physician as per prescribed questionnaire. If any complication is reported, then that will be confirmed either by the diagnosis of a registered physician (if already seen) or the patient will be advised to come and confirmed by respective specialist according to complication and specific investigation (if available). Follow-up will be done for at least 6 months after 6 months from the date of RT-PCR +ve by 3 telphonic conversation. All information will be registered in data collection form and analysed thereafter.

F. QUALITY CONTROL:

The quality control of this study will be supervised under the guidance of Professor Khan AK Azad, Ex. Principal, Professor and Head of the Department of Medicine, Dhaka Medical College, Dhaka under the SOP (Standard Operative Procedure).

G. INSTITUTIOAL APPROVAL:

We have already taken the institutional clearance from chairman, ethical committee, Sher-E-Bangla Medical College, Barishal, Bangladesh.

H. BUDGET:

Total Budget: BDT 3,50,000 (Approximately).

Detailed of the Budget:

Particulars BDT Doctor's salary- 1x6 months x 20000 120,000/- Data entry computer personel (Research associate's monthly salary 10000/-X 6) 60,000/= Specialist visit (Approximate) 40,000/= Investigations (Approximate) 1,00000/- Statistical analysis 15,000/= Stationary cost 10,000/= Others 5,000/= Total in Amount 3,50,000/=

I. FUNDING:

Contribution from researchers

J. OUTCOME:

At the end of study, we will be able to assess long-term effects of COVID-19 in patients of southern part of Bangladesh and to know its incidence. It will be possible to compare this with other studies in Bangladesh and other countries.

K. CONFLICTS OF INTEREST:

The investigator will not have any salary for himself from the fund. The salary will be provided to doctor, research associates and statistician.

Study Type

Observational

Enrollment (Anticipated)

302

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Bangladesh
      • Barisal, Bangladesh, 1207
        • Recruiting
        • HN Sarker
        • Contact:
          • HN Sarker
          • Phone Number: 01715079037

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

COVID -19 (RT-PCR +ve) patients from 1st July to 30th December, 2020 recorded in PCR Lab of Sher-E-Bangla Medical College Hospital, Barishal.

Description

Inclusion Criteria:

  • COVID-19 (RT-PCR +ve) patients age 20 years and above
  • Those patients whose mobile numbers are recorded in the register
  • Those patients who/their attendants are available on mobile phone

Exclusion Criteria:

  • Persons below 20 years of age
  • Those patients whose mobile numbers are not recorded in the register
  • Those patients who/their attendants are not available on mobile phone
  • Those who died by this time from causes unrelated to COVID-19

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Retrospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
COVID-19 (RT-PCR +ve) patients
Diagnostic test: RT-PCR
COVID 19 diagonostic test

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of long-term effects (complications) of COVID-19 in the southern part of Bangladesh
Time Frame: 6 Months
At the end of study, we will be able to assess long-term effects of COVID-19 in patients of southern part of Bangladesh and to know its incidence.
6 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sher-E-Bangla Medical College

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2021

Primary Completion (Anticipated)

October 30, 2021

Study Completion (Anticipated)

December 30, 2021

Study Registration Dates

First Submitted

August 1, 2021

First Submitted That Met QC Criteria

August 1, 2021

First Posted (Actual)

August 3, 2021

Study Record Updates

Last Update Posted (Actual)

August 3, 2021

Last Update Submitted That Met QC Criteria

August 1, 2021

Last Verified

August 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SBMC|Barisal|2020|1994

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Decide later.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on To Assess Long-term Effects of COVID-19 in Patients Who Were Affected With COVID -19

Clinical Trials on RT-PCR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe